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Because we found that WTC rats might be resistant to streptozotocin (STZ), we have elucidated the
mechanisms of resistant to the diabetogenic effects of STZ in the WTC rats. Dose response to STZ was
evaluated with glucose levels. No signiﬁcant changes in glucose level to STZ administration were ob-
served in WTC rats. Insulin secretion by suppling glucose was preserved in WTC rats even after STZ
administration. Although there was no signiﬁcant difference in gene expression of both GLUT2 and Kir6.
2, which were involved in STZ resistance, between WTC rats and Wistar rats, the expression of me-
tallothionein 2a in pancreas and liver to STZ administration of WTC rats was signiﬁcantly higher than
that of Wistar rats. Moreover, alloxan did not induce diabetes in WTC rats as same as STZ. These results
suggest that WTC rats might have powerful antioxidant property to protect β cells in pancreas. Because
the STZ-resistant property is very close characteristics to human beings, WTC rats will become a useful
animal model in diabetic researches.
& 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Type I diabetes is a chronic metabolic disorder characterized by
a loss of pancreatic islet β cell mass, decreased serum insulin, and
hyperglycemia. Although the pathogenic mechanisms of this dis-
ease have not been fully characterized, genetic, environmental,
and autoimmune factors have been postulated. Streptozotocin
(STZ)-induced diabetes in mice and rats has been used widely as
an animal model to study type I diabetes [1,2], because STZ causes
β cell necrosis and insulin-dependent diabetes mellitus in many
species [3]. Although a number of mammalian species are sensi-
tive to STZ, rabbits are highly resistant with little metabolic or
histologic evidence of β cell damage [4]. Even in rodents, mice are
much less sensitive to the diabetogenic effects of STZ than rats.
Moreover, it seems that human islets are likely to be relatively
resistant to STZ from considerable evidences in vitro and in vivo
studies [5]. WTC rats (control rats for tremor rats derived from
Kyoto: Wistar rats), a congenic strain derived from an inbreeding
line of tremor rats and bred as an inbred strain without the tm
gene. The WTC shows neither neuropathological alteration nor
abnormal phenotypes from defects in the CNS [6]. Because, un-
expectedly, we found that the WTC rats might be highly resistant
to STZ, we have elucidated the mechanisms of resistant to the
diabetogenic effects of STZ in the WTC rats.B.V. This is an open access article u
athophysiology and Animal
ces, The University of Tokyo,2. Materials and methods
2.1. Animals and induction of diabetes
All experimental procedures conformed to the animal use
guidelines of the Committee for Ethics on Animal Experiments of
The University of Tokyo. WTC (the National BioResource Project for
the Rat in Japan, Kyoto University) and Wistar rats (Japan SLC, Inc.)
were maintained under a controlled conditions at 23 °C with a 12-
h light/dark cycle, and given free access to food and water. In 12-
week-old male WTC rats and Wistar rats, the STZ (50 and 100 mg/
kg) or alloxan (150 mg/kg) were administrated to render diabetic.
Glycemia was measured using blood sample obtained from a tail
vein 4 days post-injection of these drugs with One Touch Ultra
(Johnson and Johnson, Japan) [7].2.2. Measurement of insulin
For plasma insulin concentration measurement, animals were
separated to two groups with and without after 4 days 50 mg/kg
STZ injection. Each group was further separated to two groups:
one group was fasted for overnight, another group was left for
60 min after orally given 2 g/kg glucose after fasted. Then, blood
samples were drawn from the inferior vena cava under urethane
(1 g/kg i.p.) anesthesia and centrifuged for 2 min, and the plasma
was stored at 80 °C until use. Insulin concentrations were mea-
sured by a rat insulin ELIZA kit (Shibayagi Co., Japan).nder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Table 1
The primers for RT-PCR.
gene Sense primer Antisense primer
GLUT2 CAATTTCATCATCGCCCTCT TGCAGCAATTTCGTCAAAAG
Kir6.2 CGCATGGTGACAGAGGAATG GTGGAGAGGCACAACTTCGC
Mt1a GGACCCCAACTGCTCCTG CGAGGCACCTTTGCAGACAC
Mt2a CAGCGATCTCTCGTTGATCTCC CTTGTCCGAAGCCTCTTTGC
GAPDH CTCATGACCACAGTCCATGC TTCAGCTCTGGGATGACCTT
Fig. 1. Effects of STZ on glycemia and insulin secretion in Wistar rats and WTC rats.
(A) Open bars show Wistar rat (n¼6). Closed ones show WTC rat (n¼6). *:po0.05
VS 0 mg/kg. (B) Serum insulin levels were measured with and without STZ treat-
ment in Wistar rats and WTC rats during fasted (open bars) or satiated (closed
bars). *: po0.05.
Fig. 2. The gene expressions of possible mechanisms relevance to uptake of STZ or
enhanced secretion of insulin for the STZ resistance in WTC rats. (A) GLUT2 and (B)
Kir6.2 expressions in Wistar rats (n¼6) and WTC rats (n¼6) were detected by RT-
PCR. GAPDH was used as house keeping gene.
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The relative quantity of mRNA was measured for GLUT2 and
Kir6.2, which were involved in insulin secretion and STZ-re-
sistance [8–10], and metallothionein [11] using reverse transcrip-
tion-polymerase chain reaction (RT-PCR) using TaKaRa PCR Am-
pliﬁcation kit (TaKaRa BIO INC.). The target genes’ primers for RT-
PCR are shown in Table 1 [11–14]. Tissue samples for these ex-
periments were collected from pancreas, skeletal muscles and li-
ver. The expression was calculated with Image J and the raw data
was normalized with the internal control GAPDH.2.4. Statistical analysis
Results are expressed as mean7standard error of the mean
(SEM). Statistical signiﬁcance was assessed by unpaired t-test.
Values were considered statistically signiﬁcant at po0.05.3. Results
3.1. STZ resistance in WTC rats
Wistar rats were uniformly diabetic at doses of either 50 or
100 mg/kg STZ. However, no signiﬁcant changes were observed in
WTC rats (Fig. 1A). Insulin secretion by suppling glucose was sig-
niﬁcantly increased to almost the same level in Wistar rats and
WTC rats. Although STZ injection did not affect insulin secretion
both fasting and suppling glucose in Wistar rats, insulin secretion
in WTC rats was signiﬁcantly increased in both conditions
(Fig. 1B). From these data, we considered that the WTC rats have
unique STZ-resistant characteristics.
3.2. GLUT2, Kir6.2 and metallothionein 2a mRNA expression
Because GLUT2 and Kir6.2 are involved in resistance against
STZ [8–10], we examined the gene expression of GLUT2 and Kir6.2
at pancreas by RT-PCR to evaluate STZ-resistance in WTC rats.
There was no signiﬁcant difference in gene expression of both
GLUT2 and Kir6.2 between WTC rats and Wistar rats (Fig. 2A and
Fig. 3. The gene expressions of antioxidant property in some organs. Metallothionein (MT) 1A and 2A in (A) pancreas, (B) skeletal muscle and (C) liver were detected by RT-PCR. Open
bars show their expression before STZ injection (n¼4). Closed ones show the expression after STZ injection (n¼4). GAPDH was used as house keeping gene. *: po0.05.
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dant, we further examined the gene expression of metallothionein
which was reported to have not only antioxidant but also anti
diabetic function [15]. The expression of metallothionein 2a in
pancreas and liver of Wistar rats was signiﬁcantly decreased by
STZ injection, but WTC rats did not show any changes (Fig. 3A-C).
Therefore, WTC rats might have powerful antioxidant property to
protect β cells in pancreas.
3.3. Effect of alloxan on diabetes in WTC rats
To conﬁrm this property of WTC rats, alloxan which is another
diabetogenic agent via production of reactive oxygen species wastested [15]. As shown in Fig. 4, alloxan could not induce diabetes in
WTC rats as same as STZ.4. Discussion
In this study, we found that WTC rats were highly resistant to
STZ, and clearly showed STZ-resistant characteristics in these rats.
No signiﬁcant changes in glucose level to STZ administration were
observed in WTC rats. Insulin secretion by suppling glucose was
preserved in WTC rats even after STZ administration. Although
there was no signiﬁcant difference in gene expression of both
GLUT2 and Kir6.2 between WTC rats and Wistar rats, the
Fig. 4. Effect of alloxan on glycemia in Wistar rat and WTC rat. Open bars show
Wistar rat (n¼6). Closed ones show WTC rat (n¼4). *: po0.05 VS control.
Y. Nagaki et al. / Biochemistry and Biophysics Reports 8 (2016) 157–161160expression of metallothionein 2a in pancreas and liver to STZ ad-
ministration of WTC rats was signiﬁcantly higher than that of
Wistar rats. Moreover, alloxan did not induce diabetes in WTC rats
as same as STZ. These results suggest that WTC rats might have
powerful antioxidant property to protect β cells in pancreas. Be-
cause the STZ-resistant property is very close characteristics to
human beings, WTC rats will become a useful animal model in
diabetic researches.
At ﬁrst we thought that possible mechanisms for the marked
STZ resistance in WTC rats could be impaired uptake of STZ or
enhanced secretion of insulin by pancreatic β cells. Expression in
the plasma membrane of β cells of the glucose transporter isoform
GLUT2 [17,18], which has a high Km for glucose (17 mM) [19,20]
may be required for the normal functioning of the β cell glucose
sensor [17–21]. Thus a decreased expression of GLUT2 is associated
with the β cell dysfunction of rodent models of insulin dependent
diabetes mellitus and non-insulin-dependent diabetes mellitus
and decreased GLUT2 levels may impair normal glucose uptake
and metabolism thereby preventing glucose sensing [22]. There-
fore, we evaluated the gene expression of G to know how STZ
resistance came out in WTC rat. But there were no signiﬁcant
differences of this gene between Wistar rat and WTC rat.
Closure of ATP-sensitive Kþ channels (KATP channels) in re-
sponse to metabolically generated ATP or binding of sulfonylurea
drugs stimulates insulin release from pancreatic β cells. The phy-
siological importance of KATP channels in insulin secretion was
established 420 years ago [23]. Heterozygous gain-of-function
mutations in the KCJN11 gene encoding the Kir6.2 subunit of this
channel are found in ∼47% of patients diagnosed with permanent
diabetes at o6 months of age. At substimulatory glucose con-
centrations, Kþ efﬂux through open KATP channels maintains the β
cell membrane at a hyperpolarized potential of around 70 mV,
which keeps voltage-gated Ca2þ channels closed [24]. Elevation of
the blood glucose concentration increases glucose uptake and
metabolism by the β cell, producing changes in cytosolic nucleo-
tide concentrations that cause KATP channel closure. This leads to a
membrane depolarization that opens voltage-gated Ca2þ channels
initiating β cell electrical activity and Ca2þ inﬂux, and the sub-
sequent rise in [Ca2þ]i triggers exocytosis of insulin granules.
Therefore, we also evaluated the gene expression of Kir6.2. How-
ever, we could not ﬁnd any difference in the expression of this
gene between Wistar rats and WTC rats.
On the other hand, because STZ leads β cell death by producing
oxidative stress, we investigated the gene expression of me-
tallothionein which has not only anti-oxidative but also anti-diabetic
function [25]. Because liver and skeletal muscles are glucometabolic
tissues, we investigated the gene expression in not only pancreas
but also liver and skeletal muscles. In fact, the antioxidant capacity
in Wistar rats was weakened by STZ injection, but not in WTC rats.Thus, it seems that the STZ-resistant mechanism inWTC rats may be
its own possessed antioxidant ability. Earlier studies have shown
that metallothionein has antioxidant effect by absorbing heavy
metal, such as cadmium and so on, which makes from hydrogen
peroxide to hydroxyl radical [26]. However, while it was shown that
STZ-induced diabetes related to nitric oxide, the details of the re-
active oxygen species (ROS) that STZ produces were still unknown.
STZ and alloxan, cytotoxic glucose analogs, are the most prominent
diabetogenic chemicals in diabetes research, although their cyto-
toxicity is achieved via different pathways [27]. The chemical
properties of alloxan is generation of ROS, while DNA alkylation is
thought main mechanisms of β cell death with STZ. Even though STZ
is also generator of ROS including superoxide and hydroxyl radicals.
Therefore, we investigated the response to alloxan, which induced
diabetes by producing hydroxyl radical [16], to make it clear whe-
ther the course where hydrogen peroxide changes to a hydroxyl
radical participates in STZ resistance in WTC rats. Alloxan also did
not induce diabetes in WTC rats. These results suggest that the
strength of antioxidant ability of production and resolution of hy-
drogen peroxide affects STZ resistance in WTC rats.
WTC rats are sometimes used as a control of WTC-deafness
KYOTO (WTC-dfk) rats [28]. WTC-dfk rats have a spontaneous mu-
tation of KCNQ1 gene which produces a slowly activating delayed
rectiﬁer potassium current. Mutations of the human KCNQ1 gene are
associated with the congenital long-QT syndrome and increases the
risk of sudden death from cardiac arrhythmias. Moreover, a multi-
stage genome-wide association study has shown that variants in
KCNQ1 are associated with susceptibility to diabetes [29]. WTC and
WTC-dfk strains are coisogenic and have an identical genetic back-
ground except for the dfk deletion. Therefore, WTC-dfk rats may also
have the STZ-resistant characteristics same as WTC rats. Of course
further studies will be needed, both of these strains of rats might be
useful for diabetes research in the future.
Moreover, there are a lot of animal models both type I and type
II diabetes including chemically as well as genetically induced
models in diabetes research [30]. In these models, there are many
studies about diabetes using STZ-induced diabetic rats. Human
islets are likely to be relatively resistant to STZ, but, typically, rats
are high sensitive to STZ. And so, it is more difﬁcult to discuss the
relations between the results of the studies about diabetes using
STZ-induced diabetic rats and the studies of treatments of human
diabetes. So, WTC rats are expected to give us useful information
about research on discoveries of the treatment of human diabetes.
In conclusion, WTC rats are STZ resistant for its own strong
antioxidant ability and WTC rats are expected to be useful to de-
velop studies about diabetes.Conﬂict of interest
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